May 20 (Reuters) - Tourmaline Bio Inc TRML.O:
TOURMALINE BIO ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE ONGOING PHASE 2 TRANQUILITY TRIAL EVALUATING PACIBEKITUG IN PATIENTS WITH ELEVATED HIGH-SENSITIVITY C-REACTIVE PROTEIN AND CHRONIC KIDNEY DISEASE
TOURMALINE BIO INC - PACIBEKITUG ACHIEVES SIGNIFICANT HS-CRP REDUCTIONS THROUGH DAY 90
Source text: ID:nGNXb8kycJ
Further company coverage: TRML.O
((Reuters.Briefs@thomsonreuters.com;))